SCHEDULE: Paradigm BioCapital Discloses 5.3% Stake in Erasca
Beneficial Ownership Report
Paradigm BioCapital Advisors LP and related entities have reported a 5.3% beneficial ownership stake in Erasca, Inc.'s common stock as of January 7, 2026.
Summary
- Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each reported beneficial ownership of 15,159,095 shares of Erasca, Inc. common stock.
- This ownership represents 5.3% of the class of Erasca, Inc. common stock for each of these reporting persons.
- Paradigm BioCapital International Fund Ltd. reported beneficial ownership of 13,377,027 shares, representing 4.7% of the class.
- The percentages of beneficial ownership are based on 283,711,805 shares of Common Stock outstanding as of November 5, 2025, as reported by Erasca, Inc. in its Form 10-Q filed on November 12, 2025.
- The investment is passive, and the securities were not acquired or held for the purpose of changing or influencing the control of Erasca, Inc.
Sentiment
Score: 6
Explanation: The filing discloses a new significant passive institutional investment in Erasca, Inc., which is generally viewed as a positive signal of institutional confidence, though it does not provide operational or financial performance details.
Positives
- Disclosure of a significant passive investment by Paradigm BioCapital Advisors LP and its affiliates, indicating institutional interest in Erasca, Inc.
Risks
- No specific operational or financial risks related to Erasca, Inc. were disclosed in this beneficial ownership report.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Erasca, Inc.'s future outlook.
Industry Context
This Schedule 13G filing is a disclosure of beneficial ownership and does not provide specific industry context or analysis related to Erasca, Inc.'s operations or broader industry trends.
Stakeholder Impact
- Shareholders will be aware of a new significant institutional investor, Paradigm BioCapital Advisors LP and its affiliates, holding a passive stake in Erasca, Inc.
Key Dates
| Date | Description |
|---|---|
| 11/05/2025 | Date as of which 283,711,805 shares of Common Stock were outstanding, used for percentage calculation. |
| 01/07/2026 | Date of event which required the filing of this statement. |
| 01/14/2026 | Date the Schedule 13G and Joint Filing Agreement were signed. |
Keywords
Erasca, Paradigm BioCapital, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.